Q&A: Novartis’ Eric Hughes on transplantation

With approximately 3.2 million people worldwide living with end-stage renal disease, there is immense pressure on healthcare systems with long waiting lists for kidney and liver transplants

Conatus axes staff after latest failure of Novartis-partnere...

Gilead NASH drug fails late stage trial

Gilead's top late-stage drug selonsertib, for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), has failed a phase 3 trial.

Promethera looks to Asia with €10m investment

Belgium-based liver disease specialists Promethera Biosciences have received a leg-up for the Asian market in the form of a €10 million investment from Japanese business conglomerate ITOCHU Corp

Novartis muscles into NASH fatty liver disease

Company's Eric Hughes on what it takes to be leader in NASH - and what can be learnt from hepatitis C.